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 Abstract 
 Background: In acute myeloid leukemia (AML), the internal 
tandem duplication (ITD) in the juxtamembrane domain of 
the  FLT3 (Fms-like tyrosine kinase 3) gene is one of the most 
frequent genetic alterations associated with poor prognosis. 
 Methods: A complex evaluation of the analytical properties 
of the three most frequently used detection methods  – PCR 
followed by agarose (AGE), polyacrylamide (PAGE) or 
capillary electrophoresis (CE)  – was performed on 95 DNA 
samples obtained from 73 AML patients. 
 Results: All the three methods verifi ed the presence of a 
mutant allele in 20 samples from 18 patients. AGE and PAGE 
could detect the presence of 1 % – 2 % mutant allele, while 
the detection limit of CE was 0.28 % . However, acceptable 
reproducibility (inter-assay CV  < 25 % ) of the mutant allele 
rate determination was only achievable above 1.5 % mutant/
total allele rate. The reproducibility of the ITD size determi-
nation by CE was much better, but the ITD size calculated by 
PeakScanner or GeneScan analysis was 7 % lower as com-
pared to values obtained by DNA sequencing. The presence 
of multiple ITD was over-estimated by PAGE and AGE due 
to the formation of heteroduplexes. 
 Conclusions: This study suggests the use of PCR + CE in the 
diagnostics and the follow-up of AML patients. The data fur-
ther supports the importance of proper analytical evaluation 
of home-made molecular biological diagnostic tests. 
 Keywords:  acute myeloid leukemia;  agarose gel electro-
phoresis;  capillary electrophoresis;  fms-like tyrosine kinase 
3 (FLT3);  internal tandem duplication (ITD);  polyacrylamide 
gel electrophoresis. 
 Introduction 
 The Fms-like tyrosine kinase 3 (FLT3) plays an important 
role in the activation of hematopoetic stem cells. Binding 
to its ligand results in the induction of different signaling 
pathways known to regulate cell proliferation, differentia-
tion and apoptosis of these cells. As a result, alteration in 
functionality of FLT3 can be important in the development 
of hematological malignancies  (1 – 4) . Three different types of 
activating mutations have been described in the  FLT3 gene: 
a point mutation at nucleotide position 869 of the tyrosine 
kinase domain (TKD), point mutations in the exons coding 
the juxtamembrane domain (JM) of the protein and the inter-
nal tandem duplication (ITD) in the JM domain  (1 – 4) . These 
mutations are one of the most frequent genetic alterations in 
acute myeloid leukemia (AML) and show poor prognosis, 
especially in patients without cytogenetic alterations, those 
classifi ed as the intermediate prognostic group  (3 – 6) . 
 From the three types of the FLT3 mutations, the FLT3-
ITD shows the highest frequency and clinically seems to 
be the most important. Here, a 3 – 400-base-long DNA frag-
ment is duplicated (rarely triplicated) in the region of exon 
14, intron 14 and exon 15 and sometimes short nucleotide 
additions are also combined with the duplication. In spite of 
the large nucleotide insertions the reading always remains 
in frame, resulting in an FLT3 protein with a longer JM 
domain showing a reduced inhibitory effect on the TKD 
domain  (1, 3 – 7) . 
 The detection of the FLT3-ITDs is based on a PCR using 
primers designed for the 5 ′ end of exon 14 and the 3 ′ end of 
exon 15. The presence of a longer PCR product compared to 
that amplifi ed from the wild-type allele shows the presence of 
the ITD  (8) . Different electrophoretic methods are available 
for the analysis of these PCR products. Single stranded con-
formational polymorphism  (9) , conformational sensitive gel 
electrophoresis  (10) , temperature gradient capillary electro-
phoresis  (11) , high-resolution melting analysis  (11) and dena-
turating HPLC (dHPLC)  (12, 13) are sensitive methods for the 
detection of small genetic alterations, like ITD, but are rather 
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time-consuming and labor-intensive. A simple agarose gel 
electrophoresis (AGE) is quite economical and easy to handle 
 (7, 8, 14 – 16) . Polyacrylamide gel electrophoresis (PAGE) 
has higher resolution and sensitivity but is more demanding 
and, perhaps, is less suitable for routine diagnostic purposes 
 (17 – 19) . Data are somewhat contradictory, but several lines 
of evidence suggest that the size of the ITD and the rate of 
mutant allele might have important prognostic information in 
AML  (2, 13, 15, 16, 20 – 29) . Semi-quantitative AGE or PAGE 
 (14, 20) , dHPLC  (12, 13) , the Agilent Bioanalyser  (30, 31) , 
capillary electrophoresis (CE; e.g., GeneScan analysis)  (13, 
17, 19, 22 – 29, 32, 33) or real-time quantitative PCR  (34, 35) 
can provide information about these parameters. 
 The application of home-made molecular genetic tests in 
the fi eld of hemato-oncology is rather wide-spread in routine 
diagnostic laboratories. The proper evaluation of the analyti-
cal properties of these methods prior to their routine appli-
cation  – especially in the case of the quantitative tests  – is 
essential. As such, we compared the analytical properties of 
PCR combined with AGE, PAGE and CE  – the three most fre-
quently used analytical methods  – in the detection of FLT3-
ITD in samples of AML patients. 
 Materials and methods 
 AML patients 
 Altogether 73 adult patients (age: 51.7 ± 18.5 years, 36 males, 
37 females) with AML were enrolled in this study. Patients were fol-
lowed-up by the 2nd Department of Internal Medicine of the Medical 
and Health Science Center, University of Debrecen, Debrecen and by 
the Department of Hematology of the Andr á s J ó sa County Hospital, 
Ny í regyh á za. Detailed clinical data was available in the case of 
51 patients (Supplementary Table  1 ). The work was assigned by the 
Local Ethical Committee of the University of Debrecen and informed 
consent was obtained from each donor. We have complied with the 
World Medical Association Declaration of Helsinki regarding ethical 
conduct of research involving human subjects. 
 Amplifi cation of exon 14, intron 14 and 
exon 15 of the  FLT3 gene 
 Genomic DNA was isolated from peripheral blood of AML patients 
using the QIAmp DNA Blood Minikit (Qiagen, Valencia, CA, USA). 
The region of exon 14, intron 14 and exon 15 of the  FLT3 gene was 
amplifi ed by a PCR using forward (5 ′ -ATT TAG GTA TGA AAG 
CCA GC-3 ′ ) and reverse (5 ′ -CTT TCA GCA TTT TGA CGG CAA 
CC-3 ′ ) primers (Applied Biosystems, Foster City, CA, USA)  (8) . For 
CE analysis the forward primer was labeled at the 5 ′ -end by 6-car-
boxy-fl uorescein (FAM). Each 25  μ L reaction included 200 – 500 
ng of genomic DNA, 5 pmol of each primer, 400  μ M dNTP, 2 mM 
MgCl 2 and 1 U AmpliTaq Gold polymerase (Applied Biosystems). 
When samples were prepared for the CE analysis, 0.5 pmol of each 
primers (FAM-labeled forward and non-labeled reverse) and 10 mM 
MgCl 2 was used in the PCR amplifi cation. The PCR was performed 
using the GeneAmp 2700 PCR system (Applied Biosystems) under 
the following conditions: denaturation at 95 ° C for 12 min followed 
by 35 cycles of denaturation at 94 ° C for 30 s, annealing at 56 ° C for 
1 min and extension at 72 ° C for 2 min. A fi nal extension at 72 ° C for 
10 min terminated the amplifi cation. 
 Agarose gel electrophoresis 
 The PCR products (10  μ L) were loaded with 0.5  μ L loading dye 
(bromo phenolblue: 4.2 mg/mL; xylen cyanide: 4.2 mg/mL; glycerol: 
50 v/v % ; Sigma, St. Louis, MO, USA) into slots of a 10 × 15 cm 
3 % agarose (Cambrex, East Rutherford, NJ, USA) gel in TBE buf-
fer using the wide-cell horizontal electrophoresis system (Biorad, 
Hercules, CA, USA). The electrophoresis was performed using a 
power of 10 – 11 V/cm for 1 – 2 h. The TBE buffer was changed one 
to two times during runs in order to prevent excessive warming. The 
bands were visualized by 0.4  μ g/mL ethidium bromide (Sigma) that 
was mixed into the gel and running buffer. 
 Polyacrylamide gel electrophoresis 
 The PCR products (10  μ L) were loaded with 0.5  μ L loading dye 
into slots of a 15 × 20 cm 6 % polyacrylamide/bisacrylamide (29:1) 
gel (Biorad) in TAE buffer using the Amersham SE-600 system 
(Amersham Pharmacia, Piscataway, NJ, USA). The electrophoresis 
was performed using a power of 10 – 11 V/cm for 1 – 2 h. The gel was 
stained after the run by 1  μ g/mL ethidium bromide for 20 min at 
room temperature. 
 Isolation of PCR products from the polyacrylamide gel 
 The FLT3-ITD PCR products amplifi ed from the wild and mutant 
alleles were isolated from the polyacrylamide gel by the  “ crush and 
soak ” procedure. In short, a disposable surgical knife was used to 
cut out the bands from the gel that were crushed against the wall of 
a microfuge tube (1.5 mL) with a disposable pipette tip. To the gel 
slice we added one to two times of the gel slice volume of elution 
buffer (NH 4 -acetate 0.5 M; MgSO 4 15 mM; EDTA 1 mM, 0.1 % SDS; 
Sigma). The tube was incubated for 12 – 16 h at 37 ° C on a rotary plat-
form and was centrifuged (13,800  g , 1 min,  + 4 ° C). The supernatant 
was transferred to a new tube while the polyacrylamide pellets were 
washed again with 0.5 mL elution buffer. After a repeated centrifuga-
tion the second supernatant was combined with the fi rst eluate. The 
PCR product extracted from the gel was further purifi ed using abso-
lute ethanol and 3 M Na-acetate (Sigma). 
 Capillary electrophoresis 
 The PCR products containing the 6-FAM-labeled forward primer 
were diluted 8-times in molecular biology grade water (Promega, 
Madison, WI, USA). The diluted sample (1  μ L) was mixed with 10 
 μ L formamide (Hi-Di TM formamide, Applied Biosystems) and 0.5 
 μ L GeneScan 500-ROX internal size standard (Applied Biosystems) 
and denaturated for 3 min at 96 ° C. The capillary electrophoresis of 
the samples was performed using ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems). The technical parameters were the following: 
capillary length and diameter: 47 cm and 50  μ m; capillary tempera-
ture: 60 ° C; polymer: POP6; run power and time: 15.0 kV and 60 
min; injection power and time: 2 kV and 5 – 15 s. The data collection 
was performed using the ABI Prism ™ Collection software (Applied 
Biosystems), while the runs were analyzed by the PeakScanner 
1.0 and in certain cases by the GeneScan  ®  3.1 software (Applied 
Biosystems). For size determination the local Southern method was 
applied, unless the size of a certain peak exceeded the upper range of 
the size standard, when linear regression was used. In samples of de 
novo cases we accepted signals with relative fl uorescence unit (RFU) 
 > 50 as peaks and in follow-up samples with known peak-localiza-
tions even lower RFU values (above 15) were evaluated. The area 
under the wild-type and mutant peaks was also determined and the 
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rate of mutant allele was calculated in two different ways: (i) mutant/
total allele rate = AUC 
mutant peak /(AUC mutant peaks + AUC wild-type peak ) × 100; 
and (ii) mutant/wild-type allele rate = AUC 
mutant peak /AUC wild-type peak . 
 Bidirectional sequencing of the ITDs 
 The PCR products were cleaned from the unbound dNTP, prim-
ers and other assay components by a spin column centrifugation 
(Amicon  ®  Ultra  – 0.5 mL, 30K; Millipore, Carrigtowhill, Ireland). 
A cyclic termination end sequencing reaction was performed using 
the BigDye Terminator kit (v. 3.1, Applied Biosystems) according 
to the manufacturers ’ instruction. The unbound labeled dNTP was 
removed by centrifugation using the DyeEx  ®  2.0 Spin kit (Qiagen). 
The purifi ed product (1  μ L) was mixed with 10  μ L formamide 
(Hi-Di TM formamide) and denaturated for 3 min at 96 ° C. The capil-
lary electrophoresis of the samples was performed using ABI PRISM 
310 Genetic Analyzer. The technical parameters were the following: 
capillary length and diameter: 47 cm and 50  μ m; capillary tem-
perature: 50 ° C; polymer: POP6; run power and time: 15.0 kV and 
36 min; injection power and time: 2 kV and 5 – 15 s. The data collec-
tion and analysis was performed using the ABI Prism ™ Collection 
and Sequencing Analysis 3.4.1 softwares. 
 Identifi cation of FLT3-TKD mutations 
 The determination of the presence of the FLT3-TKD mutations  – as 
part of the general diagnostic procedure for AML patients  – was per-
formed by a separate PCR + RFLP technique based on the article of 
Yamamoto et al.  (36) . The frequency of FLT3-TKD mutation was 
2/75 AML patients; combined FLT3-ITD and -TKD mutations were 
not present. In order to make the study population more homogenous 
we have enrolled in the analysis only the 73 individuals without 
FLT3-TKD mutations. 
 Statistical analysis 
 The descriptive statistics were calculated with the help of Microsoft 
Excel software. The differences in the laboratory parameters 
between the ITD-positive and -negative AML patients were evalu-
ated by the Mann-Whitney U-test, the gender distribution by the 
 χ 2 -test, while the survival data between these groups was compared 
by the Kaplan-Meier analysis. The correlation between the differ-
ent ways of ITD size determination was evaluated by Pearson ’ s re-
gression analysis. Signifi cant difference was considered in the case 
of p < 0.05. Statistical analysis was performed with the help of the 
 “ Statistica ” software. 
 Results 
 Comparison of the performance of AGE, 
PAGE and CE on FLT3-ITD detection in samples 
of patients with AML 
 Altogether 95 DNA samples of 73 adult patients with AML 
were tested for the presence of FLT3-ITD using the three dif-
ferent electrophoretic methods. Two independent samples were 
tested in the case of 18 and three samples in the case of two 
patients. We could detect the presence of at least one mutant 
allele in 20 samples of 18 patients, irrespective of the detec-
tion method used. Detailed clinical data was available only in 
the case of 51 patients and the ITD-positivity rate was 12/51 
in this cohort. Similarly to previously published data  (1 – 6) the 
FLT3-ITD positive patients had higher white blood cell count 
and LDH values and the overall and disease-free survival 
period was shorter in this group (Supplementary Table 1). 
 Based on the CE method the size of the ITD detected in 
the positive samples varied between 9 and 178 bp (median 
40 bp), while the rate of the mutant to wild type or the 
mutant to total alleles was 0.006 – 3.714 (median: 0.144) and 
0.48 % – 77.8 % (median: 12.5 % ), respectively. In nine of the 
18 ITD-positive patients more than one type of the mutant 
allele could be detected (multiple ITDs). The number of the 
cases with two and three mutant peaks on CE was seven and 
two, respectively. 
 Although all three detection methods could identify the 
FLT3-ITD positive samples, there was a discrepancy con-
cerning the number, size and intensity of the mutant alleles 
present (Figure  1 ). Consequently, the analytical properties of 
the three electrophoretic methods used for FLT3-ITD detec-
tion were evaluated. 
 Evaluation of the analytical properties of AGE, 
PAGE and CE on FLT3-ITD detection: reproducibility 
 In order to evaluate the intra- and inter-assay reproducibility of 
the tested electrophoretic methods two FLT3-ITD positive sam-
ples (P35 and P80) were amplifi ed 10-times in the same PCR 
assay on the same day and once daily on the following 9 days. 
With CE, sample P35 contained one major mutant peak and a 
hardly visible minor peak at 387 bp and 339 bp, respectively. 
In sample P80, we detected a major mutant peak at 355 bp 
and a very faint peak at 398 bp (Supplementary Figure  1 ). 
 Table  1 contains the reproducibility data of the size quanti-
tation by CE. Here, the intra-assay variability was calculated 
in two ways. First, the two positive samples were amplifi ed 
10-times in the same PCR on the same day and then each 
PCR product was injected independently into the capillary of 
the ABI310 analyzer (Table  1 ,  “ 10 cups ” ). Second, one of the 
10 PCR products from both samples was injected 10-times 
subsequently into the analyzer (Table  1 ,  “ 1 cup ” ). Regarding 
the size of the individual wild-type and mutant peaks, we 
observed very good intra- and inter-assay reproducibility (the 
CV % was typically below 0.2 % ). The size of the ITD was 
calculated as the size of the mutant allele minus the size of the 
wild-type allele. The intra- and inter-assay CV % of ITD was 
below 1 % and 2 % , respectively, if the ITD size was larger 
(above 24 bp; sample P35 – ITD2; sample P80 – ITD1 and 
 – ITD2). In the case of ITD1 of sample P35 a smaller, 9 bp 
insertion could be observed with a relatively higher intra- and 
inter-assay CV % (7 % and 11 % ). 
 Concerning the quantitation of the mutant/wild-type and 
mutant/total allele rate we obtained variable results (Table 
 2 ). In the case of sample P35 – ITD2 and sample P80 – ITD1 
the mutant/total allele rate was 65 % and 12 % , and the intra- 
and inter-assay CV % s were below 5 % . The reproducibility 
was worse when the mutant/total allele rate was  ∼ 1.2 % –
 1.5 % (sample P80 – ITD2), showing an intra-assay CV % of 
10 % – 14 % and an inter-assay CV % of 25 % . When the mutant/
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 Figure 1  Analysis of FLT3-ITD-positive and -negative DNA samples by three different electrophoretic methods. 
 Genomic DNA was amplifi ed as described in Materials and methods. The PCR products (10  μ L) were loaded on 3 % agarose (A) and 6 % 
polyacrylamide gel (B). For capillary electrophoretic analysis a different PCR protocol was used with a fl uorescently labeled forward primer. 
The samples were measured by an ABI310 analyzer, the size of the PCR products were determined by the PeakScanner software based on a 
ROX-500 size-standard (C, D, E, F, G, H, I). The size of the PCR product amplifi ed from the FLT3 wide-type allele is 331 bp, and any frag-
ments larger than this indicate the presence of ITD. (C, controls; P, patients.) 
total rate was below 1 % (sample P35 – ITD1) the reproducibi-
lity was poor: CV % s were above 50 % . 
 Although quantitative data was not gathered from the aga-
rose and polyacrylamide gel electrophoretograms in our study, 
we performed the reproducibility analysis in the case of these 
methods as well. Evaluating with agarose and polyacryl amide 
gel electrophoresis, the major mutant bands were clearly 
visible with similar size and intensity for each day and each run 
while the minor mutant bands were absent (data not shown). 
 Evaluation of the analytical properties of AGE, PAGE 
and CE on FLT3-ITD detection: analytical sensitivity 
 As a next step the detection limit of the three different elec-
trophoretic methods was compared. The DNA samples of 
ITD-positive patients (P35 or P80) were serially diluted in 
an ITD-negative DNA. The DNA concentration in the FLT3-
positive and negative samples was equal. The rate of the 
mutant to total alleles in the original samples was determined 
by CE and PeakScanner analysis and this rate in the diluted 
DNA samples was calculated based on the initial value and 
the dilution factor (Figure  2 A and B). These DNA mixes were 
amplifi ed using unlabeled primers in the FLT3-PCR and 10 
 μ L of the PCR products were loaded into an agarose or a 
polyacrylamide gel (Figure  2 A and B). The presence of the 
dominant mutant allele (mutant 2 in the case of P35) could be 
detected typically at 1 % – 2 % both on agarose and polyacryl-
amide gel (Figure  2 A and B). The minor mutant alleles were 
not detectable by these methods. 
 The serially diluted ITD-positive DNA was also tested 
using a fl uorescently labeled forward and unlabeled reverse 
primer during PCR, followed by denaturation of the PCR 
products and analysis by CE. The measured rate of the mutant 
to wild-type (Figure  2 D) or mutant to total (Figure  2 C) alleles 
was determined by PeakScanner analysis. These rates were 
expressed as a function of the calculated mutant rates in the 
diluted samples. As two different samples in different dilu-
tions were tested, the data of three independent experiments 
was pooled (Figure  2 C and D). In order to fi nd the lowest 
point of the linear part of the dilution curves a running cut-
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 Table 1  Analytical performance of FLT3-ITD size quantitation done by capillary electrophoresis. 
Wild-type allele a,b Mutant allele 1 a,b Mutant allele 2 a,b ITD 1 b ITD 2 b 
Sample P35 a 
  Intra-assay variation (1 cup) c 330.9 ± 0.2 (0.1 % ) d 339.2 ± 0.6 (0.2 % ) 387.2 ± 0.1 (0.1 % )   8.3 ± 0.6 (7.2 % ) 56.1 ± 0.3 (0.5 % )
  Intra-assay variation (10 cups) c 331.2 ± 0.1 (0.1 % ) 338.9 ± 0.4 (0.1 % ) 386.9 ± 0.1 (0.1 % )   7.7 ± 0.5 (6.5 % ) 55.7 ± 0.1 (0.2 % )
  Inter-assay variation e 330.6 ± 0.5 (0.2 % ) 339.7 ± 0.6 (0.2 % ) 387.1 ± 0.1 (0.1 % )   9.1 ± 1.0 (11.0 % ) 56.5 ± 0.6 (1.1 % )
Sample P80 a 
  Intra-assay variation (1 cup) c 330.8 ± 0.2 (0.1 % ) d 355.2 ± 0.1 (0.1 % ) 398.4 ± 0.1 (0.1 % ) 24.4 ± 0.2 (0.8 % ) 67.6 ± 0.3 (0.4 % )
  Intra-assay variation (10 cups) c 331.0 ± 0.2 (0.1 % ) 355.2 ± 0.1 (0.1 % ) 398.1 ± 0.2 (0.1 % ) 24.1 ± 0.2 (0.8 % ) 67.1 ± 0.4 (0.6 % )
  Inter-assay variation d 330.3 ± 0.5 (0.2 % ) 355.2 ± 0.1 (0.1 % ) 398.5 ± 0.3 (0.1 % ) 24.8 ± 0.4 (1.6 % ) 68.1 ± 0.7 (1.0 % )
 
a
 Two FLT3-ITD positive samples (P35 and P80) containing two mutant alleles were analyzed.  b The size of the wild-type and mutant alleles 
was determined by CE using the ABI310 analyzer and the PeakScanner software. The size of the ITDs was calculated as the size of the mutant 
alleles minus the size of the wild-type allele.  c The intra-assay variability was calculated in two ways. First, the two positive samples were ampli-
fi ed 10-times in the same PCR on the same day and then each PCR product was injected independently into the capillary of the ABI310 analyzer 
( “ 10 cups ” ). Second, one of the 10 PCR products from both samples was injected 10-times subsequently into the analyzer ( “ 1 cup ” ).   d Data 
presented show the mean ± SD values calculated from the 10 determinations. CV % (presented in brackets) was calculated as  “ SD/mean × 100 ” . 
 
e
 The two FLT3-ITD positive samples were amplifi ed and analyzed once on 10 subsequent days.
off from 0.1 % to 0.5 % for the calculated mutant/total allele 
rate (Figure  2 C) and 0.001 – 0.005 for the calculated mutant/
wild-type allele rate (Figure  2 D) was used and a linear regres-
sion line was inserted upon the data points above the actual cut-
off. The best regression coeffi cient was observed in the case 
of 0.2 % and 0.002 cut-offs for the calculated mutant/total and 
mutant/wild-type allele rates (R = 0.989 and R = 0.990, respec-
tively). The analytical sensitivity of the assay was calculated 
using the 10 data points with the lowest calculated mutant 
allele rates. The mean + 3 SD of these values were 0.28 % and 
0.0028, defi ning the detection limit of the measured mutant/
total and mutant/wild-type allele rates (Figure  2 C and D). 
 Evaluation of the analytical properties of AGE, 
PAGE and CE on FLT3-ITD detection: resolution 
 A 9 bp difference between the PCR products amplifi ed from 
the wild-type and mutant alleles in sample P114 could be 
detected by all of the applied electrophoretic methods (Figure 
 1 A, B and G). On the contrary, in the case of sample P147, 
a 370 and a 373 bp mutant allele could be detected by CE, 
but this 3 bp difference could not be resolved by agarose and 
polyacrylamide gel electrophoresis (Figure  1 A, B and I). 
 Analysis of multiple bands detected in FLT3-ITD 
positive samples by PAGE and AGE 
 In the 20 FLT3-ITD positive DNA samples, we could detect 
two, three and four mutant bands with higher molecular 
weight in 12, three and two cases and two, three and zero 
cases using PAGE and AGE, respectively. The majority of 
these larger  “ extra ” bands were not present on the CE runs 
(Figure  1 ). 
 In order to reveal their nature  – in the case of Patient N ° 55 
 – the wild-type (band 1 = 331 bp), mutant 1 (band 2 = approx. 
350 bp) and mutant 2 (band 3 = approx. 550 bp) bands were 
 Table 2  Analytical performance of FLT3-ITD rate quantitation done by capillary electrophoresis. 
Mutant 1/total,  % a,b Mutant 2/total,  % a,b Mutant 1/wild type a,b Mutant 2/wild type a,b 
Sample P35 a 
  Intra-assay variation (1 cup) c   0.39 ± 0.20 (51.3 % ) d 63.9 ± 0.5 (0.8 % ) 0.011 ± 0.006 (54.5 % ) 1.790 ± 0.035 (2.0 % )
  Intra-assay variation (10 cups) c   0.43 ± 0.34 (79.1 % ) 65.3 ± 1.6 (2.5 % ) 0.012 ± 0.009 (75.0 % ) 1.911 ± 0.114 (6.0 % )
  Inter-assay variation e   0.63 ± 0.36 (57.1 % ) 65.7 ± 2.4 (3.7 % ) 0.020 ± 0.012 (60.0 % ) 2.052 ± 0.203 (9.9 % )
Sample P80 a 
  Intra-assay variation (1 cup) c 11.9 ± 0.1 (0.8 % ) d   1.5 ± 0.1 (6.7 % ) 0.138 ± 0.001 (0.7 % ) 0.018 ± 0.002 (11.1 % )
  Intra-assay variation (10 cups) c 12.6 ± 0.2 (1.6 % )   1.2 ± 0.1 (8.3 % ) 0.146 ± 0.003 (2.1 % ) 0.014 ± 0.002 (14.3 % )
  Inter-assay variation e 12.5 ± 0.5 (4.0 % )   1.3 ± 0.3 (23.1 % ) 0.144 ± 0.007 (4.9 % ) 0.016 ± 0.004 (25.0 % )
 
a
 Two FLT3-ITD positive samples (P35 and P80) containing two mutant alleles were analyzed.  b The area under the peaks (AUC) of the wild-
type and mutant alleles was determined by CE using the ABI310 analyzer and the PeakScanner software. The rate of the mutant alleles was cal-
culated as AUC 
mutant allele /AUC mutant + wild-type alleles or as AUC mutant allele /AUC wild-type allele .  c The intra-assay variability was calculated in two ways. First, 
the two positive samples were amplifi ed 10-times in the same PCR on the same day and then each PCR product was injected independently into 
the capillary of the ABI310 analyzer ( “ 10 cups ” ). Second, one of the 10 PCR products from both samples was injected 10-times subsequently 
into the analyzer ( “ 1 cup ” ).  d Data presented show the mean ± SD values calculated from the 10 determinations. CV % (presented in brackets) was 
calculated as  “ SD/mean × 100 ” .  e The two FLT3-ITD positive samples were amplifi ed and analyzed once on 10 subsequent days. 
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 Figure 2  Sensitivity of agarose-, polyacrylamide- and capillary electrophoresis used for identifi cation of FLT3-ITD. 
 A serial dilution of an ITD-positive DNA sample (P35) was prepared using an ITD-negative DNA with the same concentration. These mixes 
were amplifi ed as described in Materials and methods and 10  μ L of the PCR product was loaded into an agarose (3 % , A) and a polyacrylamide 
(6 % , B) gel. The numbers above the lanes show the mutant/total allele rates calculated in the DNA mixes. The size of the PCR products ampli-
fi ed from the FLT3 wild-type and mutant allele are 331 and 387 bp, respectively. For capillary electrophoretic analysis a different PCR was 
applied with a fl uorescently labeled forward primer using the DNA dilution series described above. The area under the wild-type and mutant 
peaks was determined by the PeakScanner software and the measured AUC rates (C: mutant/total, D: mutant/wild type) were expressed against 
the calculated rates. The regression lines on part C and D show the best fi t on the points above 0.2 % mutant/total and 0.002 mutant/wild-type 
rate, while the detection cut-offs were defi ned as the mean + 3 SD of the lowest 10 points, respectively. Parts A and B show one representative 
experiment out of three, while parts C and D present the pooled data of three independent determinations. 
cut from the polyacrylamide gel (Figure  3 A, lane  ‘ O ’ ). Their 
DNA content was extracted and was further tested. First the 
DNA sequence was determined by bidirectional sequencing. 
Comparison of the wild-type (band 1) and mutant 1 (band 
2) sequences revealed a 21-bp-long duplication in intron14/
exon15 (c.1773_1793dup21) in mutant 1 (Figure  3 C and D). 
In mutant 2 (band 3) the mixture of the two sequences could 
be observed even after repeated excision and amplifi cation of 
this band (Figure  3 E). 
 This can suggest that the mutant band 2 is a heteroduplex 
of the wild-type and the mutant 1 bands. In order to prove this 
hypothesis two experiments were performed. First, the DNA 
of the wild-type and the mutant 1 bands isolated from the 
gel was mixed and amplifi ed together in the FLT3-ITD PCR 
(Figure  3 A, lane  “ 1/2 ” ). Second, the two isolated DNA were 
amplifi ed independently by the FLT3-PCR, and then mixed, 
denaturated at 95 ° C for 10 min and cooled down slowly (1 ° C/
min) to 4 ° C (Figure  3 A, lane  “ d/r ” ). In both cases the wild-
type, mutant 1 and mutant 2 bands were visible by PAGE. 
 Finally, the presence of the two mutant bands was also 
analyzed by a separate PCR using fl uorescence primers and 
CE by ABI 310 analyzer. Here, the heteroduplexes were fi rst 
eliminated by denaturating the PCR products by formamide 
and heating before loading into the capillary. CE revealed the 
presence of the wild-type allele (331 bp) and only one peak 
was amplifi ed from a mutant allele (350 bp; Figure  3 B). 
 Comparison of FLT3-ITD size quantitation 
determined by CE and DNA sequencing 
 It is known from previous publications that the FLT3-ITDs 
always result in an in-frame genetic alteration, i.e., the ITD 
size is a multiple of 3  (1, 3, 4) . Based on our data the ITD 
size determination performed by CE revealed values that did 
not correspond strictly to this rule. Therefore, in 10 cases we 
directly sequenced the DNA of ITD-positive samples and 
compared the number of duplicated/inserted nucleotides in 
the dominant mutant allele to the ITD size determined by CE 
(Table  3 ). The correlation between the two methods was very 
strong (R = 0.999), but the size of the duplication/insertion 
was 7 % lower if it was determined by CE (Size 
sequencing = 1.07 × 
Size CE + 0.5) (Supplementary Figure  2 A). This alteration was 
not peculiar to the PeakScanner software, which is a freeware 
program for PCR fragment analysis, as after analyzing the 
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raw data of 27 ITD peaks of 17 positive samples with the 
GeneScan software perfectly matching results were achieved 
(Size GeneScan = 1.0 × Size PeakScanner + 0.1; R = 0.999; Supplementary 
Figure 2B). 
 Discussion 
 FLT3-ITD is one of the most frequent genetic alterations in 
adult patients suffering from AML. In our study the rate of 
ITD-positivity in the whole study cohort was 24.7 % (18/73), 
showing good agreement with the majority of published data 
 (3, 4, 6, 7) . Moreover, the rate of ITD-positive samples was 
similar for all the three detection methods  – AGE, PAGE, 
CE  – used, indicating a comparable analytical sensitivity for 
the three techniques. On the other hand, some minor mutant 
bands detectable by CE were not visible on the agarose or 
polyacrylamide gels. Here, the detection limit of the assays  – 
determined by serial dilution of an ITD-positive DNA sample 
 – was 1 % – 2 % for AGE and PAGE and 0.28 % for CE. In the 
majority of the former FLT3-ITD publications similar detec-
tion sensitivities were found in the case of AGE and PAGE 
(17, 19) . Concerning CE a detection threshold of 0.8 % – 2 % was 
described for FLT3-ITD quantitation in fi ve publications  (18, 
37 – 40) , while 3 % – 10 % in another four papers  (25, 41 – 43) . 
The somewhat lower detection limit of CE observed in our 
study might be explained by the low RFU threshold used for 
peak identifi cation by us. In new samples we accepted signals 
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 Figure 3  Larger extra bands observed in the presence of ITD on polyacrylamide gel electrophoretograms are heteroduplexes of PCR products 
amplifi ed from the wild-type and the mutant alleles. 
 DNA sample of P55 was amplifi ed using the PCR described in Materials and methods. The PCR product of the wild-type allele (331 bp, band 
1) and two extra bands with higher molecular weight (band 2 and 3) could be observed using polyacrylamide gel electrophoresis (lane  “ O ” , 
part A). The three bands were excised from the gel and were reamplifi ed separately using the same PCR (Lane  “ 1 ” ,  “ 2 ” and  “ 3 ” , part A). Then 
the isolated bands 1 and 2 were mixed in equal concentrations and were amplifi ed again in the same PCR reaction (lane  “ 1/2 ” , part A) or the 
isolated bands 1 and 2 were amplifi ed independently, were mixed in equal rate and were denaturated at  + 95 ° C followed by slow cooling to 
 + 4 ° C (lane  “ d/r ” , part A). The isolated and reamplifi ed bands were also sequenced. Band 1 showed the wild-type sequence (C), band 2 had 
a 21 bp ITD (c.1773_1793dup21; D), while the sequence of band 3 was the mixture of the two former ones (E). Capillary electrophoresis of 
fl uorescently labeled and denaturated PCR products revealed only the wild-type and one mutant peak of 350 bp (B). 
 Table 3  Comparison of FLT3-ITD size determined by PaekScanner and GeneScan analysis and DNA sequencing. 
Sample a DNA sequencing a PeakScanner b GeneScan b 
P13 c.1773_1793dup21 a 19.2 ± 0.3 bp c 19.7 ± 0.4 bp
P16 c.1742_1777dup36 32.7 ± 0.2 bp 33.4 ± 0.9 bp
P35 c.1776_1833dup58 + c.1833_1834insCC 56.5 ± 0.6 bp 56.9 ± 0.5 bp
P55 c.1773_1793dup21 19.1 ± 0.2 bp 18.9 ± 0.2 bp c 
P58 c.1772_1833dup62 + c.1833_1834insGAGA 61.5 ± 0.2 bp 60.9 ± 1.4 bp
P80 c.1734G > A + c.1734_1735insCAACCAACCAACCATGCGAGGGCCTCC 24.8 ± 0.4 bp 25.0 ± 0.7 bp
P92 c.1790_1835dup46 + c.1835_1836insCCTCCCCACGG 52.5 ± 0.3 bp 52.5 ± 0.3 bp
P113 c.1762_1827dup66 61.3 ± 1.1 bp 61.5 ± 1.0 bp
P114 c.1788_1789insGGGGTCCCT 9.0 ± 0.1 bp 9.1 ± 0.1 bp
P125 c.1786_1837 + 3dup55 + c.1837 + 3_1837 + 4insCC 52.3 ± 0.6 bp 52.0 ± 1.3 bp
 
a
 The DNA of 10 ITD-positive samples was directly sequenced and the location and number of duplicated/inserted nucleotides in the domi-
nant mutant allele was determined.  b The size of the wild-type and mutant alleles was determined by CE using the ABI310 analyzer and the 
PeakScanner or GeneScan programs. The size of the ITDs was calculated as the size of the mutant alleles minus the size of the wild-type allele. 
 
c
 Data presented are mean ± SD of 3 – 10 independent determinations. 
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with RFU  > 50 as peaks and in follow-up samples with known 
peak-localizations even RFU values above 15 were accepted. 
In this way  – based on a maximal RFU signal of 6000  – a 
detection limit below 1 % could be obtained. Only some infor-
mation about the RFU threshold values is available in former 
FLT3-ITD studies. Murphy et al.  (42) used RFU = 150 as a 
threshold, while Lin et al.  (18) mentioned RFU = 110 as a very 
low peak height reaching a maximal FLT3-ITD detection sen-
sitivity of 2 % – 3 % . To ensure the presence of ITD-mutants 
with low signal intensity, analysis was repeated and declared 
positive only if the result was reproducible. 
 Although mutant alleles with very low rates were not 
detectable by AGE and PAGE, several extra bands with larger 
size were visible that were absent in the electrophoretograms 
of CE. We performed a detailed analysis of the isolated PCR 
products amplifi ed from the wild-type and mutant alleles using 
DNA sequencing and heteroduplex testing, and could prove 
that the large extra bands corresponded to the heteroduplexes 
formed by the wild-type and mutant alleles. Previous publica-
tions also suggest this phenomenon  (30, 42, 43) . Based on the 
absence of mutant alleles with very low rates and the presence 
of heteroduplexes on AGE and PAGE, the method that is suit-
able for the reliable detection of multiplex ITDs is CE. 
 By examining our patient samples we could compare 
the resolution of the applied electrophoretic methods, too. 
While any of the three methods could differentiate between 
bands/peaks which were 9 bp apart, a 3-bp-difference could 
be resolved only by CE. A similar superior resolution of 
CE-based FLT3-ITD analysis was observed in two previ-
ous publications  (18, 27) , further supporting the importance 
of this technique in multiple ITD detection. The presence of 
multiple ITDs  – determined by CE  – in our study was 50 % 
(9/18), showing somewhat higher values compared to the pre-
viously published 11 % – 32 %  (7, 13, 19 – 22, 27, 33, 42, 44) . 
This might be explained by the lower threshold used for the 
defi nition of  “ peaks ” on the CE electrophoretograms. 
 Concerning the size of ITD, basically three different 
techniques have been used for its quantitation so far. DNA 
sequencing  (7, 14, 21, 23, 26, 27, 29) , CE  (22, 24, 33, 40, 43 –
 45) and application of the Agilent Bioanalyzer  (30, 31, 46) 
showed ITD sizes varying from 3 to 400 bp, with a median 
changing between 24 and 70 bp. Our results were within these 
limits, as the observed ITD size range was 9 – 178 bp, with a 
median of 40 bp. Our data showed a good reproducibility of 
the ITD size determination by CE, as an inter-assay CV % of 
11 % was achievable even in the case of the shortest insertion 
(9 bp). The number of duplicated/inserted nucleotides was 
not divisible by three in every case, this has been reported 
in two former publications  (30, 45) , but not in other stud-
ies using Agilent Analyzer or CE. This phenomenon can be 
explained by the observed variation of about  ± 0.5 bp in the 
size of the wild-type and mutant peaks on the CE electropho-
retograms that can result in a  ± 1.0 bp change in the ITD-size. 
As such, the method that can provide the exact ITD size is 
direct sequencing of patient DNA samples or sequencing the 
isolated  – and cloned  – ITD fragments. Following the for-
mer approach we sequenced 10 samples with ITD and always 
found the duplication/insertion inframe, but these ITD sizes 
were slightly larger as compared to data obtained by CE 
and PeakScanner or GeneScan analysis. Based on literature 
data and our own experience, we suggest the usage of DNA 
sequencing for exact ITD size determination and especially 
because recent data emphasized that even the location of the 
duplication/insertion might have prognostic importance  (13) . 
 Five different methods were used so far to determine the 
rate of the mutant allele in samples of AML patients: semi-
quantitative AGE or PAGE  (14, 20) , dHPLC  (12, 13) , Agilent 
Bioanalyzer  (30, 31, 46) , real-time quantitative PCR  (34, 35) 
and CE  (13, 17, 19, 22 – 29, 32, 33) . Concerning the expres-
sion of the results two major approaches were described in 
literature; the mutant/wild-type  (13, 23 – 28, 32) or the mutant/
total allele rate  (17, 19, 20, 22, 30, 46) was used with similar 
frequency. As such we calculated both rates in our analysis. 
The median of the mutant/wild-type allele rate in our patient 
group was 0.144 (range: 0.006 – 3.714), while median of the 
mutant/total allele rate showed 12.5 % (range: 0.48 % – 77.8 % ), 
this seems to be somewhat lower than previously published 
data (range for all data and for median of the mutant/wild-type 
rate: 0.008 – 32.56 and 0.530 – 0.836; range for all data and for 
median of the mutant/total rate: 1 % – 100 % and 30 % – 47 % ). 
Most probably this can be explained again by the lower RFU 
limit used for peak defi nition in our study. Concerning the 
reproducibility of these determinations our results indicated 
that the mutant/wild-type and the mutant/total allele rate can 
be determined with an inter-assay CV %  < 25 % above 0.020 
and 1.5 % , respectively, giving the quantitation limit of these 
determinations. 
 The clinical importance of the presence of multiple ITDs 
and the ITD-size determination seems to be confl icting, and 
cannot be suggested for routine diagnostic application at the 
moment  (13, 20 – 24) . With regards to the clinical importance 
of the mutant allele rate quantitation, literature data is more 
solid and several articles showed that higher ITD-allele rate 
 – and especially the loss of the wild-type allele  (15, 16)  – is 
associated with worse overall- and disease-free survival and 
a higher relapse rate in AML  (3, 13, 20, 22, 24 – 29) . Here, 
the major problem is how to defi ne  “ high ” rate. Mostly the 
median of the allele rate values measured in a patient group 
was used as cut-off, but this varied from 0.530 to 0.836 for 
the mutant/wild-type allele rate and 30 % – 47 % in the case of 
the mutant/total rate. Based on literature data and our own 
experience, we suggest the usage of the mutant/total allele 
rate that gives more clear information to the clinician as it 
can be scaled from 0 % to 100 % . The development of a gen-
eral diagnostic cut-off needs further effort, either by pooling 
the data presently available in literature or by initiating large 
prospective trials. Until this is achieved, the 50 % limit can 
be used for samples obtained from de novo AML cases, as at 
this time-point the majority of cells are malignant, where a 
mutant/total rate above 50 % means the presence of cells with 
homozygous ITD  (47) . 
 The application of home-made molecular genetic tests in 
the detection and quantitation of FLT3-ITD is rather wide-
spread in scientifi c literature. On the other hand  – to the best 
of our knowledge  – no complex evaluation of analytical prop-
erties of the applied methods is published before. In our work 
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we defi ned the precision, inaccuracy, analytical and functional 
sensitivity, resolution, and ability to detect multiplex ITDs of 
a PCR + CE-based quantitative method and compared these 
parameters  – where applicable  – to that of PCR + AGE/PAGE-
based assays. The novel fi ndings concerning the analytical 
performance of these tests were the following; (i) though 
the CE-based assay has a very high analytical sensitivity for 
detection of FLT3-ITD mutant alleles (0.28 % ) the quantita-
tion of the rate of the mutant allele can be done reliably only 
if it is higher than 1.5 % ; (ii) the quantitation of the ITD size 
by CE can be done with high reproducibility but the accu-
racy is less perfect (7 % lower ITD-size values compared to 
DNA sequencing); (iii) the PCR + AGE/PAGE-based methods 
are not reliable for identifi cation of the presence of multiplex 
ITDs because of heteroduplex formation. Our data further 
supports the importance of the proper analytical evaluation of 
home-made molecular biological diagnostic tests. 
 In conclusion, our experimental results and data of former 
publications clearly indicate that a CE-based test seems to be 
the most suitable method for the detection and quantitation 
of the mutant/total allele rate of FLT3-ITD, and can be used 
even for routine diagnostic purposes. This assay can supple-
ment the diagnostics and follow-up of patients with AML. The 
detection of multiple ITDs and quantitation of the size of the 
duplication/insertion cannot be suggested for clinical usage at 
the moment. For research purposes, proper estimation of mul-
tiple ITD can be done by CE if the rate of the mutant allele 
is above 0.28 % , and DNA sequencing can provide reliable 
information about the size and location of ITD. 
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